Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01332630 · ClinicalTrials.gov registry record · Phase 2
TPI 287 in Breast Cancer Metastatic to the Brain
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01332630: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01332630 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01332630, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of the first part of this clinical research study is to find the highest tolerable dose of TPI-287 in patients with breast cancer that has spread to the brain. The goal of the second part of this study is to learn if TPI-287 can control breast cancer that has spread to the brain. The safety of this drug will also be studied.
Interventions
- DRUG Dexamethasone
- DRUG Ranitidine
- DRUG Benadryl
- DRUG TPI 287
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-08-16 |
| Est. Completion | 2017-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01332630
The ClinicalTrials.gov registry entry for NCT01332630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT01332630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01332630 about?
NCT01332630 is a clinical study titled "TPI 287 in Breast Cancer Metastatic to the Brain". The goal of the first part of this clinical research study is to find the highest tolerable dose of TPI-287 in patients with breast cancer that has spread to the brain. The goal of the second part of this study is to learn if TPI-287 can control breast cancer that has spread to the brain. The safet...
What is the current status of trial NCT01332630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2011-08-16. Estimated completion is 2017-04-14.
What interventions are being tested in trial NCT01332630?
The interventions under investigation include: Dexamethasone (DRUG), Ranitidine (DRUG), Benadryl (DRUG), TPI 287 (DRUG).
Who is sponsoring clinical trial NCT01332630?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.